# Treatment Protocol of Replagal for Patients With Fabry Disease

> **NCT01031173** · — · NO_LONGER_AVAILABLE · sponsor: **Shire**

## Conditions studied

- Fabry Disease

## Interventions

- **BIOLOGICAL:** agalsidase alfa

## Key facts

- **NCT ID:** NCT01031173
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2021-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01031173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01031173, "Treatment Protocol of Replagal for Patients With Fabry Disease". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01031173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*